Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

By sjmartinez • January 27, 2023

Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2022 Dec 14;67:94-101. doi: 10.1016/j.breast.2022.12.003. Epub ahead of print. PMID: 36702070.

Tags: breast cancer, Diarrhea prophylaxis, Dose escalation, early stage, health-related quality of life, Hematology/Oncology, HER2-positive, Neratinib, Publications, Tyrosine kinase inhibitor

Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality in Vital Statistics

Bor J, Bird M, Hakes JK, Himmelstein DU, Himmelstein G, Woolhandler S. Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality[...]

Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report and Literature Review

Tai JW, Roufeh EN, Reed JP. Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report[...]

Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma

Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, Lim CW, Yeung B, Lee J, Lin J, Chia C, Ng M, Ng[...]